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Abstract
Background: The effects of PIM-1 on the progression of pancreatic cancer remain unclear, and the prognostic
value of PIM-1 levels in tissues is controversial. Additionally, the expression levels and clinical value of PIM-1 in
plasma have not been reported.
Methods: The effects of PIM-1 on biological behaviours were analysed. PIM-1 levels in tissues and plasma were
detected, and the clinical value was evaluated.
Results: We found that PIM-1 knockdown in pancreatic cancer cells suppressed proliferation, induced cell cycle
arrest, enhanced apoptosis, resensitized cells to gemcitabine and erlotinib treatment, and inhibited ABCG2 and
EZH2 mRNA expression. Our results indicated that PIM-1 and the EGFR pathway formed a positive feedback loop.
We also found that PIM-1 expression in pancreatic cancer tissues was significantly upregulated and that a high level
of expression was negatively associated with prognosis (P = 0.025, hazard ratio [HR] =2.113, 95 % confidence
interval: 1.046–4.266). Additionally, we found that plasma PIM-1 levels in patients with pancreatic cancer were
significantly increased and could be used in the diagnosis of pancreatic cancer. High plasma PIM-1 expression was
an independent adverse prognostic factor for pancreatic cancer (P = 0.037, HR = 1.87, 95 % CI: 1.04–3.35).
Conclusion: Our study suggests that PIM-1 contributes to malignancy and has diagnostic and prognostic value in
pancreatic cancer.
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Abbreviations: ABCG2, Adenosine triphosphate-binding cassette superfamily G member 2; EGFR, Epidermal growth
factor receptor tyrosine kinase; EZH2, Enhancer of zeste homologue 2; PDAC, Pancreatic ductal adenocarcinoma;
PNET, Pancreatic neuroendocrine tumour
Background
Pancreatic cancer is one of the most deadly malignancies,
with an overall 5-year survival rate of 5 % [1]. One of the
main reasons for its poor prognosis is that few patients
are diagnosed at an early stage [1]; a lack of efficient
treatments and resistance to chemotherapy drugs are
additional reasons [2]. Despite considerable progress has
been made in the understanding of the molecular biology
of pancreatic carcinoma [3, 4], the molecular mechanism
of pancreatic carcinogenesis remains to be exploited.
Investigating the mechanisms of tumour progression,
early detection and resensitization of cells to
chemotherapy are important for improving the
prognosis of patients with pancreatic cancer.
PIM kinases belong to a family of serine/threonine
kinases, which is composed of three members (PIM-1,
PIM-2 and PIM-3). PIM kinases play pivotal roles in
tumour progression and anti-cancer drug resistance [5].
The role of PIM-1 in pancreatic cancer has been investi-
gated. Downregulation of PIM-1 expression was shown
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to cause cell cycle arrest, increase apoptosis and de-
crease gemcitabine and intrinsic irradiation resistance in
pancreatic cancer cell lines [6, 7]; however, the effects of
PIM-1 on cell sensitivity to epidermal growth factor re-
ceptor tyrosine kinase inhibitors (EGFR-TKIs) and on
cancer stem cells in pancreatic cancer remain unclear.
Previous reports have shown that increased EGFR ex-
pression has been found in human pancreatic cancer tis-
sue and correlated with a poor prognosis [8, 9].
Epidermal growth factor receptor (EGFR) has also been
shown to play key roles in multiple malignant processes
involved in cellular proliferation, apoptosis prevention,
drug resistance, cancer stem cell marker expression and
metastasis in pancreatic cancer [10].
The prognostic value of PIM-1 levels in tissues is con-
troversial. Reiser-Erkan et al. showed that the presence
of PIM-1 in pancreatic cancer tissues had a favourable
prognostic impact [11]; however, this finding was incon-
sistent with the oncogenic function of PIM-1 in pancre-
atic cancer, and further investigations are needed. In
addition, the expression levels and clinical value of PIM-
1 in plasma have not been reported.
The current study aimed to investigate the roles of
PIM-1 in regulating biological behaviours of pancreatic
cancer, including proliferation, apoptosis, the cell cycle,
gemcitabine and erlotinib sensitivity, and cancer stem
cells. We also analysed the expression levels of PIM-1 in
tissues, and prognostic values were evaluated. In
addition, we measured plasma PIM-1 levels and assessed
their potential clinical value for the first time.
Methods
Cell culture
Two pancreatic ductal adenocarcinoma (PDAC) cell lines,
SW1990 and MiaPaCa-2, were maintained in a humidified
incubator with 5 % CO2 at 37 °C in RPMI-1640 medium or
Dulbecco’s modified Eagle’s medium (DMEM, HyClone,
Thermo Fisher Scientific Inc., Waltham, MA, USA)
containing 10 % foetal bovine serum (FBS, HyClone).
siRNA transfection
Human PIM-1 and EGFR siRNAs and control oligos
were synthesized by Invitrogen (Shanghai, China). The
siRNAs (50–100 nM) were transfected using Lipofecta-
mine 2000 transfection reagent (Invitrogen, Carlsbad,







RNA extraction and real-time qRT-PCR
Total RNA was isolated from cells transfected with
siRNA or control oligos for 48 h using TRIzol (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s
protocol. Complementary DNA (cDNA) was synthesized
from total RNA using a reverse transcription kit (Pro-
mega, Madison, WI, USA) according to the manufac-
turer’s instructions. Real-time qRT-PCR was performed
using SYBR Green Master Mix (TaKaRa, Japan) to quan-
tify mRNA levels. GAPDH was used as an internal con-
trol. The data were analysed using the 2-ΔΔCT method.
PIM-1 Forward primer GAGAAGGACCGGATTTCC
GAC
Reverse primer CAGTCCAGGAGCCTAATGACG
EZH2 Forward primer AATCAGAGTACATGCGACT
GAGA
Reverse primer GCTGTATCCTTCGCTGTTTCC
ABCG2 Forward primer CAGGTGGAGGCAAATCT
TCGT
Reverse primer ACCCTGTTAATCCGTTCGTTTT




The growth inhibition assay was performed using Cell
Counting Kit-8 (CCK-8) reagent. To detect the effects of
PIM-1 on proliferation, cells were transfected with
siRNA or control oligos in 6-well plates for 24 h, trypsi-
nized and reseeded in 96-well plates (1,000 cells/well).
CCK-8 (10 μL/well) was added at 0, 24, 48 and 72 h and
cultured for 2.5 h at 37 °C. The optical density (OD) was
measured using a microplate reader at a wavelength of
450 nm (OD450).
To detect the effects of PIM-1 on chemosensitivity,
cells transfected with siRNA or control oligos in 6-well
plates for 24 h were trypsinized and reseeded in 96-well
plates (4,000 cells/well). Then, the cells were incubated
with different concentrations of gemcitabine (Gemzar,
Eli Lilly and Company, USA) or erlotinib (Tarceva,
Roche) for another 48 h. OD450 was measured after
adding CCK-8 reagent (10 μL/well), and the inhibition
rate was calculated.
Cell cycle assay
Cells transfected in 6-well plates (5 × 105 cells/well) for
48 h were collected, washed with cold phosphate-buffered
saline (PBS) and then fixed in 70 % ethanol overnight at
4 °C. After the cells were centrifuged twice (1000 revolu-
tions per minute (rpm) for 5 min each), they were resus-
pended in 500 μl PBS and then incubated with a solution
containing 0.1 % Triton X-100, 10 mg/ml RNase A and
1 mg/ml propidium iodide (PI). Cell cycle analysis was
performed using flow cytometry.
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Apoptosis assay
PDAC cells were transfected in 6-well plates. Twenty-four
hours later, the cells were treated with gemcitabine or
erlotinib. SW1990 cells were treated with 10 μM gemcita-
bine and 10 μM erlotinib. MiaPaCa-2 cells were treated
with 10 μM gemcitabine and 40 μM erlotinib. After the
cells were treated for 48 h, they were collected and
resuspended in binding buffer. The cells were then stained
with annexin V-FITC and PI (Beyotime, China) according
to the manufacturer’s instructions and analysed using flow
cytometry (FACScan; BD Biosciences, USA).
Western blot
Total proteins were extracted from cells transfected with
siRNA or control oligos for 48 h using RIPA buffer (Apply-
gen, Beijing, China). Total proteins (100 μg) were separated
using sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylidene
difluoride (PVDF) membranes (Millipore, Billerica, MA,
USA). Before the membranes were incubated with primary
antibodies overnight at 4 °C, they were blocked with 5 %
skim milk at room temperature for 1 h. The membranes
were then incubated with horseradish peroxidase–conju-
gated secondary antibodies at room temperature for 1 h.
Bands were visualized using an echochemiluminescence
(ECL) detection system. The following primary antibodies
were purchased from Cell Signaling Technology: PIM-1
(C93F2) rabbit mAb (3247P), EGF receptor (D38B1) XP®
rabbit mAb (4267), phospho-EGF receptor (Tyr1068)
(D7A5) XP® rabbit mAb (3777) and β-actin (13E5) rabbit
mAb (4970).
Patient and sample collection
Ninety formalin-fixed, paraffin-embedded pancreatic
adenocarcinoma specimens and matched tumour-
adjacent tissues were collected and used to construct
tissue microarrays, which were then used for detecting
PIM-1 protein expression. Ninety preoperative plasma
samples were collected from patients with pancreatic
cancer and used for detecting plasma PIM-1 levels. None
of the patients received neoadjuvant therapy before surgi-
cal resection. Preoperative plasma samples from patients
with chronic pancreatitis (19), patients with pancreatic
neuroendocrine tumours (PNETs, 20), patients with other
pancreatic tumours (29) and healthy volunteers (20 cases)
were collected as controls. Pancreatic cancer, PNETs and
other pancreatic tumours were diagnosed by pathological
examination. A diagnosis of chronic pancreatitis was
dependent on specific clinical criteria. Blood samples were
collected using non-anticoagulant tubes and centrifuged
at 3,000 rpm for 10 min. Plasma was collected and stored
at −80 °C until use.
Detection of PIM-1 expression levels using immunohisto-
chemistry (IHC)
Rabbit anti-human PIM-1 polyclonal antibodies (Abgent,
AP7932d) were used for staining. Briefly, slides were
deparaffinized in xylene and rehydrated in a graded
alcohol series. After the slides were washed with PBS,
endogenous peroxidase activity was blocked with 3 %
H2O2 for 10 min. Antigen retrieval was carried out by
incubating the slides in 0.1 % trypsin and heating them
in a microwave oven. Then, the slides were incubated
with primary antibody (diluted 1:200) overnight at 4 °C.
After the slides were washed three times with PBS, they
were incubated with horseradish peroxidase (HRP)-conju-
gated secondary antibody for 30 min at 37 °C. Diaminoben-
zidine (DAB) served as a chromogen. The slides were then
counterstained with haematoxylin. Nonimmune rabbit
serum at the same dilution served as the negative control.
PIM-1 expression levels were assessed according to the
intensity of staining and percentage of positive cells. The
following scoring system was used for the intensity of
stained cells: none (0 points), weak staining (1 point), inter-
mediate staining (2 points) and strong staining (3 points).
The following scoring system was given for the percentage
of positive cells: absent (0 points), 1–24 % of the cells (1
point), 25–49 % of the cells (2 points), 50–74 % of the cells
(3 points), and 75–100 % of the cells (4 points). A final score
was calculated by multiplying the above two scores. PIM-1
expression was considered high if the final score was greater
than 6 points and low if the final score was 6 points or less.
Enzyme-linked immunosorbent assay (ELISA)
Plasma PIM-1 levels were measured using a Human
PIM-1 ELISA Kit (Catalogue number: CSB-E11825h,
CUSABIO, Wuhan, China) according to the manufac-
turer’s instructions. Carbohydrate antigen 19–9 (CA19-
9) levels were detected using a Human CA19-9 ELISA
Kit (CSB-E04773h, CUSABIO, Wuhan, China).
Statistical analysis
Continuous data are displayed as the mean ± standard de-
viation (SD); these data were compared using analysis of
variance (ANOVA), Student’s t-test or the Mann-Whitney
U test. Categorical data are displayed as a percentage;
these data were compared using Pearson’s χ2 test or
Fisher’s exact test. A receiver operating characteristic
(ROC) curve and the area under the curve (AUC) were
used to assess the diagnostic value of plasma PIM-1 levels.
The optimal cut-off value, sensitivity and specificity were
determined using the Youden Index. AUCs were com-
pared using MedCalc Statistical Software version 13.1.2
(MedCalc Software bvba, Ostend, Belgium; http://
www.medcalc.org; 2014). Univariate survival analysis was
performed using the Kaplan-Meier method. Cox regres-
sion analysis was used for multivariate survival analysis.
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SPSS v.13.0 software (SPSS, Inc., Chicago, IL, USA) was
used for all statistical analyses. P-values less than 0.05
were considered statistically significant.
Results
Effects of siRNA-mediated knockdown of PIM-1 levels on
PDAC cells
We analysed the effect of PIM-1-specific siRNA trans-
fection on PIM-1 expression in PDAC cells by western
blot. We found that PIM-1 expression levels in PDAC
cells were significantly downregulated after PIM-1
siRNA transfection compared with those of the control
group (Additional file 1: Figure S1), which indicated that
PIM-1 levels were successfully downregulated by siRNA.
CCK8 assay demonstrated that siRNA-mediated knock-
down of PIM-1 expression levels in SW1990 and
MiaPaCa-2 cells significantly suppressed the prolifera-
tion (Fig. 1a) and increased the sensitivity of these cells
to gemcitabine and erlotinib treatment (Fig. 1b, c). Flow
cytometric analysis showed that downregulation of PIM-
1 expression decreased the percentage of S phase cells
(Fig. 1d), induced apoptosis (Fig. 2a, b) and promoted
gemcitabine- or erlotinib-induced apoptosis (Fig. 2a, b)
compared with the control group.
Fig. 1 Effects of PIM-1 on proliferation, chemosensitivity and the cell cycle. a Knockdown of PIM-1 expression was performed by transfecting PDAC
cells with PIM-1 siRNA, and proliferation was detected by CCK8 assay. b PDAC cells transfected with PIM-1 siRNA or control oligos were incubated
with different concentrations of gemcitabine for 48 h. Cell viability was evaluated by CCK8 assay, and the inhibition rate at each concentration was
calculated. c Transfected cells were treated with different concentrations of erlotinib; the inhibition rate at each concentration was calculated.
d MiaPaCa-2 cells transfected with PIM-1 siRNA or control oligos were cultured for 48 h and then collected for cell cycle analysis. The results for the
population of cells in each phase of the cell cycle were evaluated by flow cytometry. The data are displayed as the mean ± SD (*, P < 0.05)
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We also investigated the expression levels of the pancre-
atic cancer stem cell markers ABCG2 [12] and EZH2 [13]
by qRT-PCR, and we found that ABCG2 and EZH2 mRNA
expression levels were significantly decreased following
siRNA-mediated knockdown of PIM-1 expression (Fig. 3).
PIM-1 and the EGFR signalling pathway form a feedback loop
We also investigated the mechanisms by which PIM-1
regulates pancreatic cancer progression. We found that
PIM-1 and the EGFR signalling pathway formed a
feedback loop and that siRNA-mediated knockdown of
PIM-1 decreased EGFR and pTyr1068-EGFR expression
(Fig. 4a). While blocking the EGFR signalling pathway
with erlotinib or EGFR siRNA suppressed PIM-1 expres-
sion in SW1990 and MiaPaCa-2 cells (Fig. 4b, c).
Expression levels and clinical value of PIM-1 in tissues
PIM-1 protein expression levels in tissues were detected
using IHC. PIM-1 protein was located in the cytoplasm
or in both the cytoplasm and nucleus. Twenty-four of 90
pancreatic cancer samples showed low-level PIM-1 pro-
tein expression, and 66 of 90 pancreatic cancer samples
showed high-level PIM-1 protein expression. In contrast,
37 of 90 tumour-adjacent samples showed low-level
Fig. 2 siRNA-mediated knockdown of PIM-1 increased apoptosis of SW1990 and MiaPaCa-2 cells. a Flow cytometric analysis of annexin-FITC/PI staining of
SW1990 cells that were transfected with PIM-1 siRNA or control oligos and then treated with gemcitabine, erlotinib, or neither for 48 h. b Flow cytometric
analysis of annexin-FITC/PI staining of transfected MiaPaCa-2 cells that were treated with drugs. The data are displayed as the mean ± SD (*, P< 0.05)
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Fig. 3 PIM-1 downregulation decreased the expression levels of cancer stem cell markers in pancreatic cancer. qRT-PCR was used to detect the mRNA
expression levels of the indicated cancer stem cell markers. GAPDH was used as an internal control. The data are displayed as the mean ± SD (*, P< 0.05)
Fig. 4 PIM-1 and the EGFR signalling pathway formed a feedback loop. a PDAC cells were transfected with PIM-1 siRNA and control oligos for 48 h,
and protein levels of PIM-1, EGFR and pTyr1068-EGFR were detected using western blots. b PDAC cells were treated with different concentrations of
erlotinib to block the EGFR pathway, and protein levels of PIM-1, EGFR and pTyr1068-EGFR were detected using western blots. c Knockdown of EGFR
expression using siRNA. Western blots were used to detect protein levels of PIM-1, EGFR and pTyr1068-EGFR
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PIM-1 protein expression, and 53 of 90 tumour-adjacent
samples showed high-level PIM-1 protein expression.
Thus, PIM-1 protein levels were increased significantly
in cancer tissues compared with tumour-adjacent tissues
(P = 0.041) (Fig. 5a).
In addition, we evaluated the clinical value of PIM-1
expression levels in tissues. Eighty-seven of 90 cases with
complete medical records were included in the analysis.
There was no correlation between the expression levels of
PIM-1 and clinicopathological parameters, including sex,
age, tumour location, differential degree, TNM staging,
diabetes or perineural invasion (Additional file 2: Table
S1). Univariate analysis indicated that TNM staging and
PIM-1 expression level were potential prognostic factors
for pancreatic cancer (Additional file 3: Table S2; Fig. 5b).
Multivariate analysis indicated that TNM staging (II/III/
IV) and PIM-1 expression (high) were independent
adverse prognostic factors (P = 0.023, HR = 1.882, 95 % CI:
1.085–3.266; P = 0.025, HR = 2.113, 95 % CI: 1.046–4.266,
respectively) (Additional file 3: Table S2).
Expression levels and diagnostic value of plasma PIM-1 levels
Plasma PIM-1 levels in patients with pancreatic cancer
have not been described. In the current study, we
measured plasma PIM-1 levels and then assessed their
diagnostic value in pancreatic cancer. Plasma PIM-1
levels in patients with pancreatic cancer (29.8 ± 47.7 ng/
ml) were significantly higher than in healthy volunteers
(0.21 ± 0.31 ng/ml), in patients with chronic pancreatitis
(3.11 ± 5.2 ng/ml), in patients with other pancreatic
tumours (8.75 ± 6.6 ng/ml) or in patients with PNETs
(15.7 ± 8.9 ng/ml) (P = 0.000, P = 0.000, P = 0.000 and
P = 0.01, respectively). In addition, plasma levels of
PIM-1 in patients with pancreatic cancer were sig-
nificantly higher than were those in all control sub-
jects combined (29.8 ± 47.7 ng/ml vs. 7.21 ± 8.3 ng/ml,
P = 0.000) (Fig. 5c).
Furthermore, we assessed the diagnostic value of
plasma PIM-1 levels using ROC curve analysis. Plasma
PIM-1 levels displayed diagnostic values for distinguish-
ing patients with pancreatic cancer from healthy volun-
teers, patients with chronic pancreatitis, and patients
with other pancreatic tumours (P = 0.000, P = 0.000, and
P = 0.001, respectively). When patients with pancreatic
cancer were distinguished from healthy volunteers,
plasma PIM-1 levels were significantly superior to
CA19-9 levels (0.984 vs. 0.897, respectively; P = 0.0019),
particularly in terms of sensitivity (95.6 vs. 74.4 %)
(Fig. 6a). When patients with pancreatic cancer were
distinguished from patients with chronic pancreatitis,
Fig. 5 Expression levels and prognostic value of PIM-1 in the tissues and plasma of patients with pancreatic cancer. a Expression levels of PIM-1
in tissues were detected using IHC (200× magnification). b Kaplan-Meier survival analysis of patients with pancreatic cancer based on PIM-1
expression in tumours. c Expression levels of PIM-1 in plasma were detected by ELISA. All controls included healthy volunteers, patients with
chronic pancreatitis, patients with other pancreatic tumours and patients with pancreatic neuroendocrine tumours (PNETs)
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plasma PIM-1 levels were also significantly superior to
CA19-9 levels (0.895 vs. 0.785, respectively; P = 0.0178),
but the specificity was lower (77.8 vs. 88.9 %) (Fig. 6a).
The AUC, sensitivity and specificity are shown in
Table 1.
Association between plasma PIM-1 levels and clinicopath-
ologic parameters and survival analysis in patients with
pancreatic cancer
Eighty-two patients with pancreatic cancer with complete
medical records and follow-up information were divided
into high- and low-level expression groups according to
median plasma PIM-1 levels. We found that plasma PIM-
1 levels were associated with age, tumour location and
TNM staging (P = 0.031, P = 0.000 and P = 0.013, respect-
ively) (Additional file 4: Table S3). Patients with high
plasma PIM-1 levels had advanced-stage tumours. Univar-
iate analysis showed that M staging, TNM staging, margin
status and PIM-1 levels were potential prognostic factors
for pancreatic cancer (P = 0.000, P = 0.000, P = 0.002 and
P = 0.026, respectively) (Additional file 5: Table S4). Multi-
variate analysis indicated that TNM staging (advanced)
Fig. 6 Diagnostic and prognostic value of plasma PIM-1 levels. a Diagnostic value of PIM-1 and CA19-9 was analysed using ROC curves. The AUC
values were compared using the Z test. b Kaplan-Meier survival analysis of patients with pancreatic cancer based on PIM-1 expression levels in plasma.
Table 1 Diagnostic values of plasma PIM-1 and CA19-9 levels
PIM-1 CA19-9
AUC Sensitivity Specificity AUC Sensitivity Specificity
(%) (%) (%) (%)
Pancreatic cancer VS
Healthy volunteers
0.984 95.6 100 0.879 74.4 100
Pancreatic cancer VS
Chronic pancreatitis
0.895 87.8 77.8 0.785 65.6 88.9
Pancreatic cancer VS
Other pancreatic tumors
0.706 51.1 86.2 0.841 65.6 100
Pancreatic cancer VS
PNET
0.529 —— —— 0.888 81.1 95
Note: AUC area under the curve, CI confidence interval, PNET pancreatic neuroendocrine tumors
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and plasma PIM-1 levels (high) were independent adverse
prognostic factors (P = 0.000, HR = 1.88, 95 % CI: 1.17–
2.57; P = 0.0037, HR = 1.87, 95 % CI: 1.04–3.35, respect-
ively) (Additional file 5: Table S4, Fig. 6b).
Discussion
PIM kinases play pivotal roles in the development and
progression of pancreatic cancer. PIM-1 is involved in
regulating cell proliferation, the cell cycle, apoptosis and
chemoresistance in multiple tumours, including pancre-
atic cancer [5, 14]. PIM-3 is overexpressed in patients with
pancreatic cancer and is a prognostic indicator related to
poor survival in these patients [15, 16]. Downregulation of
PIM-3 expression can decrease cell proliferation, invasion,
chemoresistance, radioresistance and angiogenesis in
pancreatic cancer [7, 17, 18]. The potential mechanisms
by which PIM-3 promotes tumours include upregulation
of pSTAT3Try705, pSurvivinThr34 and VEGF, activation
of the AKT/β-catenin pathway, phosphorylation of Bad,
and inhibition of Bcl-xl [15, 16, 18, 19]. However, the
regulatory roles and mechanisms of PIM-1 in pancreatic
cancer are still unclear. We found that siRNA-mediated
knockdown of PIM-1 inhibited cell proliferation, increased
apoptosis, decreased the percentage of S-phase cells,
resensitized cells to gemcitabine treatment, and promoted
gemcitabine-induced apoptosis, consistent with the results
reported in previous studies [6, 7, 20, 21]. We also demon-
strated that downregulation of PIM-1 increased the sensi-
tivity of PDAC cells to erlotinib, enhanced erlotinib-
induced apoptosis, and decreased cancer stem cell marker
expression. To our knowledge, the effects of PIM-1 on
erlotinib sensitivity and cancer stem cells in pancreatic
cancer have not previously been reported in the literature.
One mechanism by which PIM-1 regulates the cell cycle
is through PIM-1 phosphorylation of Cdc25A and
Cdc25C, which results in an increase in cells in G1/S and
G2/M transition [22, 23]. In addition, PIM-1 can phos-
phorylate P21cip1/waf1 and P27kip1, which are involved in
regulation of the cell cycle [24, 25]. PIM-1 is also involved
in regulating apoptosis through blockade of multiple
apoptotic signals. PIM-1 phosphorylates Bad at Ser112,
which results in proteasomal degradation, thus protecting
cells from the pro-apoptotic effects of Bad [26]. PIM-1
can also regulate apoptosis by phosphorylating ASK1 at
Ser83 [27] or phosphorylating PRAS40 at Thr246 [28].
PIM-1 likewise plays a role in the regulation of chemore-
sistance. PIM-1 increases the phosphorylation of ABCG2
at Thr362, and downregulation of PIM-1 increases the
chemosensitivity of prostate cancer cells [29]. PIM-1 has
also been shown to regulate P-glycoprotein (Pgp, ABCB1)
by protecting Pgp, a 150 kD protein, from degradation
and enabling Pgp glycosylation and cell surface transloca-
tion [30]. These studies may partly account for the effects
of PIM-1 on pancreatic cancer but do not explain the
mechanisms by which PIM-1 regulates the sensitivity of
cells to erlotinib or affects the expression of pancreatic
cancer stem cell markers.
Cancer cells present different mechanisms of drug
resistance including innate mechanisms that result in
modulation of intracellular signaling pathways [31]. One
potential mechanism may be that PIM-1 and the EGFR
signalling pathway form a feedback loop. Siu and
colleagues found that knockdown of PIM-1 upregulated
the expression of MIG6, a negative regulator of EGFR sig-
nalling, which then inactivated EGFR signalling [20]. The
EGFR signalling pathway also plays a role in the regulation
of PIM-1 expression. Stimulation of the EGFR pathway
with EGF or TGF-α induced PIM-1 upregulation and
nuclear translocation in head and neck squamous cell
carcinoma (HNSCC) cell lines [32]. Conversely, downreg-
ulation of EGFR in HeLa cells may suppress PIM-1
mRNA expression [33]. Our study is the first to verify the
feedback loop between PIM-1 and the EGFR signalling
pathway in pancreatic cancer. Activation of the EGFR
signalling pathway resulted in cell proliferation, anti-
apoptosis, angiogenesis, metastasis, and chemoresistance
to gemcitabine and EGFR-TKIs and promoted the activity
of stem cells in various cancers [34, 35]. Thus, the poten-
tial mechanism by which PIM-1 affects sensitivity to the
chemotherapy drug erlotinib or the expression of pancre-
atic cancer stem cell markers in pancreatic cancer may be
by regulating the EGFR signalling pathway. Numerous
PIM‑1 inhibitors, such as flavonoid inhibitors, ETP‑45299,
SGI‑1776 and AZD1208, have been developed [36–39].
SGI‑1776, as a first-generation inhibitor, has high anti-
tumour activity in vivo and in vitro by inhibiting FLT3,
cyclin D1, MCL, Myc and Pgp [40, 41]. Thus, the
combination of PIM-1 inhibitor with erlotinib may be
new method for pancreatic cancer therapy in future
investigations [26].
PIM-1 levels significantly increased in not only cancer
tissues but also cancer stroma as reported in a previous
study [11]. The roles and mechanisms of increased levels
of PIM-1 in stroma have not been elucidated in pancreatic
cancer. Zemskova et al. found that PIM‑1 was highly
expressed in human prostate cancer stroma [42]. PIM-1
could induce fibroblast cells to secrete extracellular
matrix, collagen 1A1, chemokine CCL5, and platelet‑der-
ived growth factor receptor to enhance the ability of fibro-
blasts to differentiate into myofibroblasts and express
known markers of cancer-associated fibroblasts (CAFs)
[42]. Additionally, PIM-1 promoted prostate cancer cell
migration and invasion by phosphorylating CXCR4 at
Ser‑339 [43]. These findings suggest that PIM‑1 may have
a significant potential in cancer metastasis by crosstalk
with the tumour microenvironment. The roles and mech-
anisms by which PIM-1 levels increase in pancreatic
cancer stroma should be demonstrated in future studies.
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The prognostic value of PIM-1 levels in cancer tissues
remains controversial. Peng et al. demonstrated that the
PIM-1 expression level in colon cancer tissues was not
prognostic [44]. Liu et al. found that high PIM-1 expres-
sion levels were associated with poor prognosis in patients
with oesophageal squamous cell carcinoma [45]. However,
Reiser-Erkan and colleagues showed that the presence of
PIM-1 in pancreatic cancer cells had a favourable
prognostic impact [11]. In the present study, we demon-
strated that the PIM-1 expression level in tissue was an
independent poor prognostic factor, which is consistent
with the oncogenic role of PIM-1 in pancreatic cancer.
Further studies are needed to investigate the prognostic
value of PIM-1 in cancers.
Then, we analysed expression levels and clinical value of
plasma PIM-1 for the first time. We found that plasma
PIM-1 levels in patients with pancreatic cancer were
significantly increased and were better than CA19-9 levels
in differentiating patients with pancreatic cancer from
healthy volunteers and patients with chronic pancreatitis;
thus, the plasma PIM-1 level may serve as a new circulat-
ing marker for the diagnosis of pancreatic cancer. Further-
more, we found that plasma PIM-1 levels were associated
with TNM staging. Patients with high plasma PIM-1 levels
had advanced-stage tumours. Therefore, the plasma PIM-
1 level could be a new marker for TNM staging of pancre-
atic cancer. We also found that a high plasma PIM-1 level
was an independent adverse prognostic factor and could
serve as a new prognostic marker for pancreatic cancer.
The present study has several limitations. First, the
pancreatic cancer tissues analysed in the study were
obtained from surgical resection, so there was inherent
bias to analyse the relativity between PIM-1 expression
levels and TNM stages because few patients were eligible
for surgical resection. Second, the pancreatic cancer tissue
and plasma samples available in our study were not
paired. Further studies are needed to investigate the cor-
relation of PIM-1 expression levels between tumour tissue
and plasma. Third, we did not measure EGFR expression
levels in pancreatic cancer tissues or plasma. The feedback
loop of PIM-1 and the EGFR signalling pathway would be
strengthened if the relevance of expression levels between
PIM-1 and EGFR could be verified in pancreatic cancer.
In conclusion, PIM-1 and the EGFR pathway form a
feedback loop, which contributes to the malignancy of
pancreatic cancer. PIM-1 levels in tissues and plasma
were independent prognostic factors, and PIM-1 may be
a new prognostic biomarker for pancreatic cancer.
Plasma PIM-1 levels also displayed potential diagnostic
value in pancreatic cancer.
Conclusions
PIM-1 is upregulated in pancreatic cancer tissues and
plasma and may serve as an independent adverse
prognostic factor for pancreatic cancer. Knockdown of
PIM-1 expression in pancreatic cancer cells suppressed
proliferation, induced cell cycle arrest, enhanced
apoptosis, resensitized cells to gemcitabine and erlotinib
treatment, and inhibited ABCG2 and EZH2 mRNA
expression. Thus, PIM-1 may be a biomarker and poten-
tial therapeutic target in pancreatic cancer.
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